A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: Impact on management

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Routine testing for inherited and acquired thrombophilia defects is frequently performed in pediatric patients with thromboembolic events (TEEs). No consensus guidelines exist regarding the timing of testing or the type of patients to be tested. The primary objective of our study, therefore, was to determine whether thrombophilia testing during the acute TEE setting affected clinical management in pediatric patients. A secondary aim included estimation of potential harm from thrombophilia testing. We retrospectively reviewed data on all pediatric patients diagnosed with a TEE during a 1-year period. Fifty-two (51%) of 102 patients with a TEE underwent thrombophilia testing during the acute phase, with 26 patients (50%) having a positive test result during the acute phase. Only 12% of patients tested were confirmed to have a thrombophilia eventually, yielding a false-positive rate of ~7% for testing when performed in the acute setting. There were no changes to the acute management, regardless of a positive or negative result. Testing resulted in unnecessary blood loss in 12 patients younger than 1 year and acute testing cost approximately $82 000. Our data show that thrombophilia testing during acute TEEs in pediatric patients did not impact clinical management. There is also a potential for false-positive tests leading to unnecessary long-term anticoagulation. These findings suggest against thrombophilia testing during acute TEE setting in children.

Original languageEnglish (US)
Pages (from-to)2386-2391
Number of pages6
JournalBlood Advances
Volume1
Issue number25
DOIs
StatePublished - Nov 28 2017

Fingerprint

Clinical Audit
Thrombophilia
Pediatrics
Guidelines
Costs and Cost Analysis

ASJC Scopus subject areas

  • Hematology

Cite this

A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events : Impact on management. / Gavva, Chakri; Sarode, Ravindra; Zia, Ayesha.

In: Blood Advances, Vol. 1, No. 25, 28.11.2017, p. 2386-2391.

Research output: Contribution to journalArticle

@article{9cf197094cbd4c2f947c81123ddd96b8,
title = "A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events: Impact on management",
abstract = "Routine testing for inherited and acquired thrombophilia defects is frequently performed in pediatric patients with thromboembolic events (TEEs). No consensus guidelines exist regarding the timing of testing or the type of patients to be tested. The primary objective of our study, therefore, was to determine whether thrombophilia testing during the acute TEE setting affected clinical management in pediatric patients. A secondary aim included estimation of potential harm from thrombophilia testing. We retrospectively reviewed data on all pediatric patients diagnosed with a TEE during a 1-year period. Fifty-two (51{\%}) of 102 patients with a TEE underwent thrombophilia testing during the acute phase, with 26 patients (50{\%}) having a positive test result during the acute phase. Only 12{\%} of patients tested were confirmed to have a thrombophilia eventually, yielding a false-positive rate of ~7{\%} for testing when performed in the acute setting. There were no changes to the acute management, regardless of a positive or negative result. Testing resulted in unnecessary blood loss in 12 patients younger than 1 year and acute testing cost approximately $82 000. Our data show that thrombophilia testing during acute TEEs in pediatric patients did not impact clinical management. There is also a potential for false-positive tests leading to unnecessary long-term anticoagulation. These findings suggest against thrombophilia testing during acute TEE setting in children.",
author = "Chakri Gavva and Ravindra Sarode and Ayesha Zia",
year = "2017",
month = "11",
day = "28",
doi = "10.1182/bloodadvances.2017009514",
language = "English (US)",
volume = "1",
pages = "2386--2391",
journal = "Blood advances",
issn = "2473-9529",
publisher = "American Society of Hematology",
number = "25",

}

TY - JOUR

T1 - A clinical audit of thrombophilia testing in pediatric patients with acute thromboembolic events

T2 - Impact on management

AU - Gavva, Chakri

AU - Sarode, Ravindra

AU - Zia, Ayesha

PY - 2017/11/28

Y1 - 2017/11/28

N2 - Routine testing for inherited and acquired thrombophilia defects is frequently performed in pediatric patients with thromboembolic events (TEEs). No consensus guidelines exist regarding the timing of testing or the type of patients to be tested. The primary objective of our study, therefore, was to determine whether thrombophilia testing during the acute TEE setting affected clinical management in pediatric patients. A secondary aim included estimation of potential harm from thrombophilia testing. We retrospectively reviewed data on all pediatric patients diagnosed with a TEE during a 1-year period. Fifty-two (51%) of 102 patients with a TEE underwent thrombophilia testing during the acute phase, with 26 patients (50%) having a positive test result during the acute phase. Only 12% of patients tested were confirmed to have a thrombophilia eventually, yielding a false-positive rate of ~7% for testing when performed in the acute setting. There were no changes to the acute management, regardless of a positive or negative result. Testing resulted in unnecessary blood loss in 12 patients younger than 1 year and acute testing cost approximately $82 000. Our data show that thrombophilia testing during acute TEEs in pediatric patients did not impact clinical management. There is also a potential for false-positive tests leading to unnecessary long-term anticoagulation. These findings suggest against thrombophilia testing during acute TEE setting in children.

AB - Routine testing for inherited and acquired thrombophilia defects is frequently performed in pediatric patients with thromboembolic events (TEEs). No consensus guidelines exist regarding the timing of testing or the type of patients to be tested. The primary objective of our study, therefore, was to determine whether thrombophilia testing during the acute TEE setting affected clinical management in pediatric patients. A secondary aim included estimation of potential harm from thrombophilia testing. We retrospectively reviewed data on all pediatric patients diagnosed with a TEE during a 1-year period. Fifty-two (51%) of 102 patients with a TEE underwent thrombophilia testing during the acute phase, with 26 patients (50%) having a positive test result during the acute phase. Only 12% of patients tested were confirmed to have a thrombophilia eventually, yielding a false-positive rate of ~7% for testing when performed in the acute setting. There were no changes to the acute management, regardless of a positive or negative result. Testing resulted in unnecessary blood loss in 12 patients younger than 1 year and acute testing cost approximately $82 000. Our data show that thrombophilia testing during acute TEEs in pediatric patients did not impact clinical management. There is also a potential for false-positive tests leading to unnecessary long-term anticoagulation. These findings suggest against thrombophilia testing during acute TEE setting in children.

UR - http://www.scopus.com/inward/record.url?scp=85073810620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073810620&partnerID=8YFLogxK

U2 - 10.1182/bloodadvances.2017009514

DO - 10.1182/bloodadvances.2017009514

M3 - Article

C2 - 29296888

AN - SCOPUS:85073810620

VL - 1

SP - 2386

EP - 2391

JO - Blood advances

JF - Blood advances

SN - 2473-9529

IS - 25

ER -